Results 61 to 70 of about 100,658 (276)

Extrarenal manifestations of complement mediated thrombotic microangiopathies

Frontiers in Pediatrics, 2014
Thrombotic microangiopathies (TMA) are rare but severe disorders, characterized by endothelial cell activation and thrombus formation leading to hemolytic anemia, thrombocytopenia and organ failure.
Johannes eHofer, Alejandra eRosales, Caroline eFischer, Thomas eGiner   +3 more
doaj   +1 more source

TTP-like syndrome and its relationship with complement activation in critically ill patients with COVID-19: A cross-sectional study

Heliyon, 2023
Background: The covid-19 disease has caused many deaths worldwide since December 2019. Many thromboembolic events, such as VTE and TTP, have been reported since the beginning of this pandemic.
Mohammadreza Ardalan, Mohammadreza Moslemi, Azin Pakmehr, Sepideh Zununi Vahed, Amirreza Khalaji, Hamidreza Moslemi, Amir Vahedi   +6 more
doaj   +1 more source

Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure [PDF]

, 2016
BACKGROUND AND AIMS: Circulating levels of von Willebrand factor (vWF) predict mortality in patients with cirrhosis. We hypothesized that systemic inflammation in acute-on-chronic liver failure (ACLF) will stimulate endothelium, increase vWF levels, and ...
Amirtharaj, GJ, Balasubramanian, KA, Eapen, CE, Elias, E, Goel, A, Mackie, I, Prasanna, KS, Ramachandran, A, Sajith, KG, Zachariah, U   +9 more
core   +1 more source

Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib

Case Reports in Hematology, 2018
Drug-induced thrombotic microangiopathies (DTMAs) are increasingly being recognized as an important category of thrombotic microangiopathies (TMAs). Cancer therapeutic agents including proteasome inhibitors (PIs) are among the most common medications ...
Suheil Albert Atallah-Yunes, Myat Han Soe   +1 more
doaj   +1 more source

Diclofenac-induced thrombotic thrombocytopenic purpura with concomitant complement dysregulation: a case report and review of the literature

Journal of Medical Case Reports, 2019
Background Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are two forms of thrombotic microangiopathies. They are characterized by severe thrombocytopenia, microangiopathic hemolysis, and thrombosis, leading to a systemic inflammatory ...
Jose Perez Lara, Yaneidy Santana, Maneesh Gaddam, Asghar Ali, Sandeep Malik, Misbahuddin Khaja   +5 more
doaj   +1 more source

Risk factors for silent cerebral infarction in immune‐mediated thrombotic thrombocytopenic survivors

British Journal of Haematology, EarlyView.
Summary Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission.
Binish Javed, Jia Yu, Jenna Brown, Jay Meade, Gloria F. Gerber, Michael B. Streiff, Peggy Kraus, Samuel Merrill, Allyson M. Pishko, Jennifer Yui, Rakhi P. Naik, Robert A. Brodsky, Doris D. Lin, Shruti Chaturvedi   +13 more
wiley   +1 more source

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

Haemophilia, EarlyView.
ABSTRACT Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Tyler W. Buckner, Shannon L. Carpenter, Nabil Daoud, Christine L. Kempton, Lucy Lee, Lynn Malec, Thomas W. McLean, Paul Morton, Carrie O'Neill, Janice M. Staber, Michael Wang, Stacy E. Croteau, Michael Recht   +12 more
wiley   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

Clinical characteristics, treatments, and outcomes of thrombotic thrombocytopenic purpura treated with plasma exchange in Japan: a nationwide inpatient database study

Renal Replacement Therapy, 2023
Background Plasma exchange (PEX) has been the primary treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) since the 1990s. Daily PEX is recommended in international guidelines, but PEX was only reimbursed up to three times weekly ...
Yuji Yamada, Hiroyuki Ohbe, Hideo Yasunaga, Hidetomo Nakamoto, Yoshitaka Miyakawa   +4 more
doaj   +1 more source

The global aHUS registry: methodology and initial patient characteristics [PDF]

, 2015
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, genetically-mediated systemic disease most often caused by chronic, uncontrolled complement activation that leads to systemic thrombotic microangiopathy (TMA) and renal and other end-organ ...
Ardissino, Gianluigi, Ariceta, Gema, Cohen, David, Cole, J. Alexander, Frémeaux-Bacchi, Véronique, Gasteyger, Christoph, Greenbaum, Larry A., Johnson, Sally, Licht, Christoph, Ogawa, Masayo, Schaefer, Franz, Vande Walle, Johan   +11 more
core   +2 more sources